Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant. A retrospective study from the CMWP (Chronic Malignancies Working Party) of the EBMT

Myelodysplastic syndromes (MDS) mostly affect elderly patients with a median age at diagnosis of 74 years [1 –3]. The International Prognosis Scoring System (IPSS) prognostic classification reflects the heterogeneous clinical course of MDS and may be used to guide therapeutic decisions [4]. Supportive care with transfusions and erythropoietin stimulating agents may compensate cytopenia in patients with l ow risk disease. On the other hand, the treatment of high risk MDS aims at postponing its progression to acute leukemia, e.g.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research